Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > August 19, 2024
Daily News
August 19, 2024
- Xarelto Copycats Earn Blessing, AG Might also Get on Board
August 19, 2024
- Eisai’s ALS Therapy, Amgen’s TED Drug Up for Review on Aug. 26
August 19, 2024
- August Generic Approval List Includes AGs for at Least 3 APIs, Acofide and More
August 19, 2024
- Japan Approves Equa, Onglyza Generics towards December Listing, 1st DPP-4 Copycat on Horizon?
August 19, 2024
- Otsuka Rolls Out Therapeutic App for Depression in US
August 19, 2024
- Fabhalta, Omjjara, Avigan Now Available in Japan
August 19, 2024
- Takeda Gets Japan Approval for Low-Dose Form of Ninlaro
August 19, 2024
- Insud/ASKA’s Birth Control Pill Approved in South Korea
August 19, 2024
- Breyanzi Broadens Label for Follicular Lymphoma in Japan: BMS
August 19, 2024
- Chugai Files DMD Gene Therapy Elevidys in Japan
August 19, 2024
- Rinvoq Filed for Giant Cell Arteritis in Japan: AbbVie
August 19, 2024
- Eisai’s Leqembi Now Approved in UAE
August 19, 2024
- MHLW Announces Simplified New Process for Drug Delisting
August 19, 2024
- Business Revamp “Just Getting Started”: Sumitomo Pharma CEO
August 19, 2024
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…